What Is Behind the Growing Adoption of Nanomedicine? Approved Products, Funding, and Regulation

Nanomedicine is gaining traction across the pharmaceutical and biotechnology industries as researchers develop advanced drug delivery systems, targeted therapies, and nanoscale formulations for complex diseases. Regulatory approvals, increased research investments, and advances in lipid nanoparticle technology are supporting the development and commercialization of these medical applications. Kings Research reports that the global nanomedicine market generated a valuation of USD 263.68 billion in 2025 and is forecast to reach USD 695.42 billion by 2033, at a CAGR of 12.83% over the forecast period (2026-2033).

Beyond this forecast, the sector's commercial potential depends on how effectively research moves into clinical development and regulatory approval. The European Medicines Agency (EMA) reported in January 2025 that most approved nanotechnology-based medicines use optimized formulations of active substances that had already received approval. Meanwhile, public funding remains an important contributor to research infrastructure and early-stage development. The FY2026 U.S. budget request proposed USD 459.0 million for NIH nanotechnology research, although Congress subsequently funded NIH overall at a level 1.0% above FY2025.

Understanding these developments provides a clearer view of the factors supporting nanomedicine growth, the regulatory considerations influencing commercialization, and the opportunities emerging across pharmaceutical and biotechnology research.

What Is Nanomedicine?

Nanomedicine applies nanoscale materials and technologies to medical applications, including disease diagnosis, prevention, and treatment. The EMA describes nanomedicines as products in which at least one nanoscale component imparts specific properties, such as preferential distribution or controlled release. Definitions vary across regions, reflecting differences in regulatory approaches and product classification.

Nanomedicine applications include nanomaterials-based drug delivery systems, imaging agents, and therapeutic formulations designed to improve the distribution and stability of active pharmaceutical ingredients.

What Is the Global Outlook for Nanomedicine Through 2033?

According to Kings Research, the global nanomedicine market size is projected to generate revenue of USD 695.42 billion by 2033. This outlook reflects the expanding application of nanotechnology across drug delivery, diagnostics, disease monitoring, and targeted therapies. Increasing research and development activities, alongside investments from pharmaceutical and biotechnology companies, are supporting the development of nanotechnology-based medical solutions.

Growing interest in formulations that improve therapeutic delivery, protect sensitive drug molecules, and support treatments for complex diseases is also contributing to the sector's expansion. Lipid-based carriers, polymeric nanoparticles, and other nanoscale platforms are receiving attention across pharmaceutical research.

These developments also highlight the importance of translating laboratory research into commercially viable products. Regulatory requirements, manufacturing capabilities, and clinical evidence will remain important considerations as developers advance new formulations.

What Is Driving the Growth of Nanomedicine?

Several scientific and technological developments are supporting the growing adoption of nanomedicine. Advances in lipid nanoparticles (LNPs) and messenger RNA (mRNA) technology are among the most significant contributors, particularly because these platforms enable the delivery of complex therapeutic molecules, including nucleic acids.

Growing research activity across cancer treatment, neurological disorders, and gene therapies is also expanding the potential applications of nanomedicine. Pharmaceutical companies and academic institutions are investigating new formulations that improve therapeutic delivery, stability, and treatment precision.

Lipid nanoparticles and mRNA

Lipid nanoparticles have gained considerable attention through their application in mRNA-based vaccines. These delivery systems encapsulate and protect genetic material, helping transport it into target cells. Their commercial application in authorized vaccines has also provided a foundation for further research into nucleic acid-based therapeutics.

The EMA's January 2025 overview of authorized nanotechnology-based medicinal products includes Comirnaty, an mRNA-based COVID-19 vaccine, and Onpattro, an siRNA-based medicine. Both are classified as lipid-based nanoparticle products, illustrating the use of this delivery technology across different therapeutic approaches.

Research is also extending into emerging cancer treatments. A review published in Pharmaceutics in October 2025 examines developments in lipid nanoparticle-based drug delivery for cancer therapy, including research involving CRISPR-Cas9 gene editing, RNA interference, and immunotherapy. These approaches are being investigated for their potential to deliver complex therapeutic payloads to tumor cells.

Further developments across the RNA therapeutics and RNAi therapeutics fields are contributing to research opportunities for nanoscale delivery platforms.

How Many Nanomedicines Reach Patients?

The transition from laboratory research to commercial availability remains a lengthy process involving material characterization, preclinical assessment, clinical evaluation, and regulatory review.

The National Nanotechnology Initiative's April 2026 report highlights the work of the National Cancer Institute's Nanotechnology Characterization Laboratory. According to the report figures cited in the brief, the laboratory has tested more than 600 nanomaterials, with 24 collaborators progressing to clinical trials and several associated formulations reaching the market.

These figures demonstrate how specialized research facilities contribute to the progression of nanomedicine from early-stage material characterization to clinical development and commercial application. Characterization laboratories help researchers assess the physical and chemical properties of nanomaterials and generate information required for subsequent development stages.

Understanding particle characteristics, manufacturing consistency, and product-specific quality attributes when evaluating nanomedicines is important. These considerations influence the evidence required to establish the safety, quality, and effectiveness of individual formulations.

What Holds the Field Back?

Despite growing research activity, several technical and regulatory challenges influence the commercial development of nanomedicines.

Complex manufacturing processes increase production costs, particularly for formulations that require precise control over particle size, distribution, and surface properties. Maintaining consistent product characteristics during large-scale manufacturing also requires specialized infrastructure and quality control procedures.

Regulatory requirements present another consideration. Differences in product classification, characterization requirements, and available guidance across jurisdictions can increase the complexity of development and commercialization. As a result, manufacturers must account for product-specific quality and safety requirements throughout the development process.

United States: FDA

The U.S. Food and Drug Administration (FDA) issued its final guidance, Drug Products, Including Biological Products, that Contain Nanomaterials, in April 2022. The document outlines considerations for developing human drug products, including biological products, in which nanomaterials are present in the finished dosage form.

The FDA clarifies that its guidance documents represent the agency's current thinking and contain nonbinding recommendations. They do not establish legally enforceable requirements. The guidance addresses products in which nanomaterials function as active ingredients or inactive ingredients, including carriers containing active pharmaceutical ingredients.

European Union: EMA

The European Union regulates nanotechnology-based medicinal products through its existing medicinal product and medical device frameworks, with the applicable pathway depending on product classification. The European Medicines Agency (EMA) has also published reflection papers and regulatory considerations addressing specific nanotechnology-based products.

The EMA report highlights product classification as an important regulatory consideration. For example, NBTXR3, a radioenhancer, is classified as a medical device in the European Union and as a medicinal product in the United States. This distinction illustrates how a product's primary mode of action can influence its regulatory classification and the applicable approval pathway.

China: NMPA

China has introduced three interim technical guidelines specifically addressing nano drugs. Issued by the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA), these documents cover quality control studies, nonclinical pharmacokinetic studies, and nonclinical safety evaluation. They were issued and implemented in August 2021.

These guidelines provide technical direction for evaluating the quality, pharmacokinetic characteristics, and safety of nanomedicines during development. They establish specific reference points for developers preparing nano drug formulations for regulatory evaluation in China.

Japan: PMDA

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) provides specific regulatory documents for nanomedicines, including guidance on liposome drug products and reflection papers on siRNA-loaded nanotechnology-based drug products. Both documents were issued in March 2016.

The liposome guidance addresses pharmaceutical development and considerations related to quality, manufacturing, and nonclinical evaluation. The siRNA reflection paper outlines considerations for the pharmaceutical development and evaluation of nucleic acid formulations using nanotechnology-based carriers.

These differences highlight the importance of jurisdiction-specific regulatory planning. Companies developing nanomedicines for international markets must consider product classification, formulation characteristics, and the technical evidence expected by individual regulatory authorities.

Is U.S. Public Funding for Nanotechnology Research Rising?

Public funding remains an important component of the nanomedicine research ecosystem, supporting fundamental nanoscience, biomedical applications, and research infrastructure. The FY2026 U.S. budget request presented a mixed outlook for this funding landscape, particularly for NIH-supported nanotechnology research.

The National Nanotechnology Initiative's April 2026 budget supplement requested approximately USD 1.45 billion for nanotechnology research and development across participating federal agencies. Within this proposal, NIH nanotechnology funding was estimated at USD 459.0 million for FY2026, compared with USD 761.7 million in FY2025 estimates and USD 764.9 million in FY2024 actual funding.

These figures represent proposed funding levels for FY2026 rather than enacted NIH nanotechnology expenditure.

The final congressional funding outcome provides a different perspective. According to the Congressional Research Service's May 2026 report, Congress provided NIH with USD 47.493 billion in total program funding for FY2026, representing a 1.0% increase over FY2025. This outcome differed from the administration's budget request, which had proposed reducing NIH's overall program funding by 40.6%.

The distinction is important when assessing the funding outlook for nanomedicine research. The NIH-wide appropriation reflects the overall research funding environment, while the proposed nanotechnology allocation represents a specific research category. A published FY2026 enacted NIH nanotechnology-specific figure is unavailable in the cited materials.

Conclusion

Nanomedicine is advancing through developments in approved drug formulations, lipid nanoparticle technology, public research investments, and regulatory guidance. While existing products demonstrate the clinical and commercial application of nanoscale drug delivery, the progression of emerging formulations depends on manufacturing consistency, product characterization, clinical evidence, and regulatory evaluation.

The FY2026 U.S. funding outcome also highlights the importance of distinguishing proposed research allocations from final congressional appropriations when assessing the public investment landscape.

According to Kings Research, the field is expected to witness substantial expansion through 2033, reflecting growing opportunities across pharmaceutical development and therapeutic applications. For companies assessing these opportunities, understanding the relationship between scientific progress, regulatory requirements, and commercialization remains essential.

Explore the nanomedicine report for further insights into industry developments and the forecast outlook. Related opportunities across the precision medicine field also highlight the expanding role of advanced technologies in pharmaceutical development.

FAQs

How fast is nanomedicine expected to grow?

According to Kings Research, the global nanomedicine sector is projected to expand at a CAGR of 12.83% between 2026 and 2033. Expanding applications in drug delivery, diagnostics, and targeted therapies, alongside research investments and advancements in nanoscale formulations, are supporting its development across pharmaceutical and biotechnology applications.

Does the EU have a specific regulatory framework for nanomedicines?

The European Union regulates nanomedicines through existing medicinal product and medical device legislation, supplemented by EMA reflection papers. These documents address selected nanomedicine categories and provide guidance on pharmaceutical development, quality assessment, and clinical evaluation.

What did the 2026 U.S. budget request for nanotechnology research?

The President's FY2026 budget requested approximately USD 1.45 billion for the National Nanotechnology Initiative. Within this proposal, NIH nanotechnology funding was estimated at USD 459.0 million. These amounts represent requested funding rather than final enacted allocations for individual research categories.

What are lipid nanoparticles used for in medicine?

Lipid nanoparticles serve as delivery systems for therapeutic molecules, including mRNA and small interfering RNA. Authorized products listed by the EMA include Comirnaty, an mRNA vaccine, and Onpattro, an siRNA-based medicine. Research also examines their potential applications in gene editing and cancer therapy.

How are nanomedicines used in hospitals and clinics?

Nanomedicines are used in healthcare settings for applications such as targeted drug delivery, cancer treatment, and other specialized therapies. Their administration may require clinical supervision, controlled dosing, and monitoring, depending on the formulation and therapeutic application.

Is the FDA's nanomaterials guidance binding?

The FDA's guidance for drug products containing nanomaterials outlines the agency's current recommendations for product development and evaluation. FDA guidance documents carry advisory status rather than establishing legally enforceable requirements for the agency or the public.